Abstract:Clinical trials have demonstrated that concurrent administration of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) with chemotherapy agents does not improve overall survival in patients with non-small-cell lung cancer. Autophagy might play an important role in the resistance to EGFR-TKIs and/or chemotherapy agents. In the present study, we found that a combination of gefitinib and cisplatin generated antagonistic effects in EGFR-TKI-sensitive cells and that previously inhibiting autophagy by chloroquine could produce synergistic effect by increasing apoptosis.Background: Four large clinical trials have shown that concurrent administration of an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), such as gefitinib or erlotinib, with chemotherapy agents does not improve overall survival (OS) in unselected patients with advanced non-small-cell lung cancer (NSCLC). In the present study, the role of autophagy in the combination of gefitinib and cisplatin on EGFR-TKI-sensitive human lung cancer cell line was investigated. Moreover, whether simultaneous autophagy inhibition treatment increases the antitumor activity was explored. Materials and Methods: The PC9 cell was exposed to either gefitinib or cisplatin alone or together. Cell viability was measured using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. The cytotoxic interaction between gefitinib and cisplatin was determined using coefficient of drug interaction (CDI) analysis. The cell cycle distribution and apoptosis were measured using flow cytometry. Alterations in the autophagy and apoptosis signaling pathway were measured using Western blot assays. Results: Coadministration of gefitinib and cisplatin resulted in antagonistic activity to tumor cell proliferation. However, the addition of chloroquine (CQ), an autophagy inhibitor, overcame the antagonistic effects, as demonstrated by CDI analysis and Annexin V-FITC/propidium iodide (PI) assays. In addition, gefitinib administration led to cell G1 phase arrest, which might have contributed to the antagonistic activity between gefitinib and cisplatin. However, the addition of CQ did not deregulate cell cycle arrest, indicating that other mechanisms might be involved. The Annexin V-FITC/PI assays showed that the addition of CQ significantly the increased the ratio of apoptosis cells. Also, immunoblotting assays exhibited increased Bax and decreased Bcl-2, suggesting that autophagy inhibition by CQ could increase cell apoptosis and thus overcome the antagonistic effects. Conclusion: The combination of gefitinib with cisplatin generates antagonistic effects on EGFR-TKI-sensitive cells. However, inhibiting autophagy produces a synergistic effect, suggesting that gefitinib and cisplatin combined with an autophagy inhibitor (especially CQ) might be a beneficial strategy to overcome the antagonistic effects between EGFR-TKIs and chemotherapeutic agents. (C) 2015 Elsevier Inc. All rights reserved.

Plk1 (Polo Like Kinase 1)-Dependent Autophagy Facilitates Gefitinib-Induced Hepatotoxicity By Degrading Cox6a1 (Cytochrome C Oxidase Subunit 6a1)

Knockdown of PLAT Enhances the Anticancer Effect of Gefitinib in Non-Small Cell Lung Cancer

Integrin Β1-Mediated Acquired Gefitinib Resistance in Non-Small Cell Lung Cancer Cells Occurs Via the Phosphoinositide 3-Kinase-dependent Pathway.

An effective drug sensitizing agent increases gefitinib treatment by down regulating PI3K/Akt/mTOR pathway and up regulating autophagy in non-small cell lung cancer.

Inhibition of Autophagy by YC-1 Promotes Gefitinib Induced Apoptosis by Targeting FOXO1 in Gefitinib-Resistant NSCLC Cells

EGFR Tyrosine Kinase Inhibitors Activate Autophagy As a Cytoprotective Response in Human Lung Cancer Cells

Autophagy Inhibition Overcomes the Antagonistic Effect Between Gefitinib and Cisplatin in Epidermal Growth Factor Receptor Mutant Non–Small-Cell Lung Cancer Cells

Synergistic Effects of FGFR1 and PLK1 Inhibitors Target a Metabolic Liability in KRAS‐mutant Cancer

PLIN2 Confers Gefitinib Resistance by Inhibiting Cell Apoptosis Via Activation of EGFR/AKT/survivin in PC9R Cells

Induction of CYP1A1 Increases Gefitinib-Induced Oxidative Stress and Apoptosis in A549 Cells.

BI6727, a polo-like kinase 1 inhibitor, synergizes with gefitinib to suppress hepatocellular carcinoma cells via a G2/M arrest mechanism

Targeting the COX2/MET/TOPK signaling axis induces apoptosis in gefitinib-resistant NSCLC cells

Proteasome activation is critical for cell death induced by inhibitors of polo-like kinase 1 (PLK1) in multiple cancers

ERK inhibition represses gefitinib resistance in non-small cell lung cancer cells.

Exosomes derived from gefitinib-treated EGFR-mutant lung cancer cells alter cisplatin sensitivity via up-regulating autophagy.

The Combination of Gefitinib and Acetaminophen Exacerbates Hepatotoxicity Via ROS-Mediated Apoptosis.

Liver X receptors agonist GW3965 re-sensitizes gefitinib-resistant human non-small cell lung cancer cell to gefitinib treatment by inhibiting NF-κB in vitro

FOXO3 mutation predicting gefitinib-induced hepatotoxicity in NSCLC patients through regulation of autophagy

PCK2 induces gefitinib resistance by suppresses ferroptosis in non-small cell lung cancer

Gefitinib Facilitates PINK1/Parkin-mediated Mitophagy by Enhancing Mitochondrial Recruitment of OPTN

Methylation-modulated PFTK1 regulates gefitinib resistance via Wnt/β-catenin signaling in EGFR mutant non-small-cell lung cancer cells